Skip to Content
Merck
  • Cancer cells deploy lipocalin-2 to collect limiting iron in leptomeningeal metastasis.

Cancer cells deploy lipocalin-2 to collect limiting iron in leptomeningeal metastasis.

Science (New York, N.Y.) (2020-07-18)
Yudan Chi, Jan Remsik, Vaidotas Kiseliovas, Camille Derderian, Ugur Sener, Majdi Alghader, Fadi Saadeh, Katie Nikishina, Tejus Bale, Christine Iacobuzio-Donahue, Tiffany Thomas, Dana Pe'er, Linas Mazutis, Adrienne Boire
ABSTRACT

The tumor microenvironment plays a critical regulatory role in cancer progression, especially in central nervous system metastases. Cancer cells within the cerebrospinal fluid (CSF)-filled leptomeninges face substantial microenvironmental challenges, including inflammation and sparse micronutrients. To investigate the mechanism by which cancer cells in these leptomeningeal metastases (LM) overcome these constraints, we subjected CSF from five patients with LM to single-cell RNA sequencing. We found that cancer cells, but not macrophages, within the CSF express the iron-binding protein lipocalin-2 (LCN2) and its receptor SCL22A17. These macrophages generate inflammatory cytokines that induce cancer cell LCN2 expression but do not generate LCN2 themselves. In mouse models of LM, cancer cell growth is supported by the LCN2/SLC22A17 system and is inhibited by iron chelation therapy. Thus, cancer cells appear to survive in the CSF by outcompeting macrophages for iron.

MATERIALS
Product Number
Brand
Product Description

Deferoxamine mesylate salt, European Pharmacopoeia (EP) Reference Standard
Sigma-Aldrich
Rat serum
Sigma-Aldrich
Formalin solution, neutral buffered, 10%, histological tissue fixative
Sigma-Aldrich
2,5-Dihydroxybenzoic acid, 98%
Sigma-Aldrich
Triton X-100, for molecular biology
Sigma-Aldrich
Triton X-100, laboratory grade
Sigma-Aldrich
Mouse serum
Sigma-Aldrich
D-Penicillamine, 98-101%